3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Interventions
pembrolizumab
219
Carboplatin
218
Specimen Handling
196
Cisplatin
188
Magnetic Resonance Spectroscopy
167
Radiotherapy
152
Bevacizumab
142
Gemcitabine
135
Cyclophosphamide
133
Drug Therapy
118
Capecitabine
117
Paclitaxel
112
Oxaliplatin
110
Biopsy
105
venetoclax
102
Nivolumab
101
Rituximab
83
tislelizumab
81
durvalumab
81
toripalimab
77
Fluorouracil
73
Etoposide
72
Dexamethasone
69
sintilimab
67
Radiosurgery
67
Docetaxel
67
Pemetrexed
65
atezolizumab
64
Azacitidine
63
Injections
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
Histamine H2 Antagonists
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled